Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical group developing new therapies and treatments for deadly blood diseases - Submits investigational new drug application seeking authorisation from the US Food & Drug Administration to begin a phase 1 clinical trial of its lead product chemic antigen receptor T-cells, or Hemo-Car-T, for treating acute myeloid leukemia. Read More
(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday not separately reported by Alliance News: Read More
(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it successfully raised GBP4.1 million in a placing of new shares, with the fresh cash to be used to progress its Hemo-CAR-T product candidate into clinical trials. Read More
Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical group developing new therapies and treatments for deadly blood diseases - Completes third process qualification run for the manufacture of HEMO-CAR-T cells. Says the HEMO-CAR-T cells will be tested by third party to ensure quality. The three process runs are required by the US Food & Drug Administration to begin clinical trials. Following completion of all tests across all PQ runs, data will be compiled for inclusion in the investigational new drug submission pack. HEMO-CAR-T cells are being developed the potential treatment of acute myeloid leukemia, a blood and bone marrow cancer. Read More
(Alliance News) - Hemogenyx Pharmaceuticals PLC shares jumped early Monday, after the company announced the discovery of a single target protein for use against multiple dangerous viruses. Read More
Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Successfully completes its second process qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells. The company says it was followed by analytical release tests to verify the quality of the manufactured cells. The run is the second of three identical manufacturing runs required by the US Food and Drug Administration for the submission of an investigational new drug application. The IND application is needed in order to commence phase one clinical trials of HEMO-CAR-T cells. Read More
(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Wednesday. Read More
(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said it has completed the final development run for its manufacturing process of HEMO-CAR-T cells. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said it has been awarded a patent for its bi-specific antibody in China. Read More
(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday named Koen van Besien as its new medical director. Read More
Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Opens its new custom-engineered laboratory in New York. The facility includes 10,000 rentable square feet of lab space, including two clean rooms for cell therapy manufacturing. Company says it is now able to manufacture cells in-house, accelerating and simplifying the commercialisation of its cell therapy product candidates. Intends to initially focus on the production of its HEMO-CAR T cell therapy for leukaemia. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Wednesday and not separately reported by Alliance News: Read More
TRADING UPDATES: Equals Group and IQGeo expect strong 2021 Read More
TRADING UPDATES: Silver Bullet faces cyber attack; Zoltav to delist Read More
TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru Read More
TRADING UPDATES: Victoria and Brickability report revenue progress Read More